Conference Call Today at 4:30 p.m. Eastern Time IRVINGTON, N.Y., Nov. 12, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced financial results for the three and nine months ended September 30, 2014. Business Highlights for the Third Quarter and Subsequent Weeks: Announced that in the report the use of MelaFind reduced by 61% benign biopsies of the...
↧